Melnick Lab

Publications

2016

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma., M.G. Cardenas; W. Yu; W. Béguelin; M.R. Teater; H. Geng; R.L. Goldstein; E. Oswald; K. Hatzi; S.N. Yang; J. Cohen; R. Shaknovich; K. Vanommeslaeghe; H. Cheng; D. Liang; H.Je Cho; J. Abbott; W. Tam; W. Du; J.P. Leonard; O. Elemento; L. Cerchietti; T. Cierpicki; F. Xue; A.D. MacKerell; A.M. Melnick, J Clin Invest, 2016 09 01, 126, 9, p.3351-62, (2016) PubMed

A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations., D. Han; X. Lu; A.H. Shih; J. Nie; Q. You; M.Michelle Xu; A.M. Melnick; R.L. Levine; C. He, Mol Cell, 2016 08 18, 63, 4, p.711-719, (2016) PubMed

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia., S. Li; F.E. Garrett-Bakelman; S.S. Chung; M.A. Sanders; T. Hricik; F. Rapaport; J. Patel; R. Dillon; P. Vijay; A.L. Brown; A.E. Perl; J. Cannon; L. Bullinger; S. Luger; M. Becker; I.D. Lewis; L.Bik To; R. Delwel; B. Löwenberg; H. Döhner; K. Döhner; M.L. Guzman; D.C. Hassane; G.J. Roboz; D. Grimwade; P.J.M. Valk; R.J. D'Andrea; M. Carroll; C.Y. Park; D. Neuberg; R. Levine; A.M. Melnick; C.E. Mason, Nat Med, 2016 07, 22, 7, p.792-9, (2016) PubMed

Genetic and epigenetic heterogeneity in acute myeloid leukemia., S. Li; C.E. Mason; A. Melnick, Curr Opin Genet Dev, 2016 02, 36, , p.100-6, (2016) PubMed

PTEN opposes negative selection and enables oncogenic transformation of pre-B cells., S. Shojaee; L.N. Chan; M. Buchner; V. Cazzaniga; K.Nehir Cosgun; H. Geng; Y.Hua Qiu; M.Dühren von Minden; T. Ernst; A. Hochhaus; G. Cazzaniga; A. Melnick; S.M. Kornblau; T.G. Graeber; H. Wu; H. Jumaa; M. Müschen, Nat Med, 2016 Apr, 22, 4, p.379-87, (2016) PubMed

Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia., Z. Chen; S. Shojaee; M. Buchner; H. Geng; J.Woong Lee; L. Klemm; B. Titz; T.G. Graeber; E. Park; Y.Xim Tan; A. Satterthwaite; E. Paietta; S.P. Hunger; C.L. Willman; A. Melnick; M.L. Loh; J.U. Jung; J.E. Coligan; S. Bolland; T.W. Mak; A. Limnander; H. Jumaa; M. Reth; A. Weiss; C.A. Lowell; M. Müschen, Nature, 2016 06 02, 534, 7605, p.138, (2016) PubMed

Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma., N.S. Saba; D. Liu; S.E.M. Herman; C. Underbayev; X. Tian; D. Behrend; M.A. Weniger; M. Skarzynski; J. Gyamfi; L. Fontan; A. Melnick; C. Grant; M. Roschewski; A. Navarro; S. Beà; S. Pittaluga; K. Dunleavy; W.H. Wilson; A. Wiestner, Blood, 2016 07 07, 128, 1, p.82-92, (2016) PubMed

Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma., T. Dupont; S.Ning Yang; J. Patel; K. Hatzi; A. Malik; W. Tam; P. Martin; J. Leonard; A. Melnick; L. Cerchietti, Oncotarget, 2016 Jan 19, 7, 3, p.3520-32, (2016) PubMed

General Biomarker Recommendations for Lymphoma., L. Rimsza; Y. Fedoriw; L.M. Staudt; A. Melnick; R. Gascoyne; M. Crump; L. Baizer; K. Fu; E. Hsi; J.W.C. Chan; L. McShane; J.P. Leonard; B.S. Kahl; R.F. Little; J.W. Friedberg; L. Kostakoglu, J Natl Cancer Inst, 2016 12, 108, 12, p., (2016) PubMed

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia., M.R. Luskin; P.A. Gimotty; C. Smith; A.W. Loren; M.E. Figueroa; J. Harrison; Z. Sun; M.S. Tallman; E.M. Paietta; M.R. Litzow; A.M. Melnick; R.L. Levine; H.F. Fernandez; S.M. Luger; M. Carroll; S.R. Master; G.B.W. Wertheim, JCI Insight, 2016 Jun 16, 1, 9, p., (2016) PubMed